| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910981 | Lung Cancer | 2015 | 9 Pages |
Abstract
Maintenance therapy with either a continuation or a switch strategy yields a statistically significant but clinically modest improvement in OS for patients with advanced NSCLC. Factors that may predict benefit from maintenance therapy (tumor histology, PS, or EGFR mutation status), as well as economic considerations should be taken into account before initiating maintenance therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Fei Zhou, Tao Jiang, Wanrong Ma, Guanghui Gao, Xiaoxia Chen, Caicun Zhou,